New Research Identifies Optimal Uses for 18 Popular HA Fillers
In response to growing demands for injectable hyaluronic acid (HA) filler, clinical researchers sought to provide data on the performance of 18 of the most popular fillers on the market. The research
--published by the Journal of the American Society of Plastic Surgeons
--collected rheologic and physicochemical measurements on 18 HA filler products including Juvéderm (Allergan); Belotero Balance (Anteis, S.A. for Merz Pharma); Restylane (Q-Med AB/Galderma); and Teosyal (Teoxane) among others. The researcher examined the impact of rheologic parameter elastic modulus (G') and HA concentration on swelling and cohesion to distinguish between the fillers, as higher G' fillers tend to be firmer with more elastic compression response and lower G's tend to be softer and less elastic. The research found that Restylane Fynesse was the filler with the lowest G,' while Restylane Lyft had the highest. Researchers further detailed recommended uses for optimal patient outcomes.
Researchers Find Brodalumab Effective for Psoriasis Patients with Skin of Color
published in the American Journal of Clinical Dermatology examined the efficacy, safety, and health outcomes in patients with skin of color--self-categorized as Black, Asian, Hispanic/Latino-- receiving brodalumab over 52 weeks. Tested against a group of caucasian patients, the findings suggest that brodalumab may be superior to ustekinumab in Black, Asian, and Hispanic/Latino subgroups. The study’s authors noted that a larger sample size of non-caucasian patient would be needed to make a definitive statement. While there is no clear biologic basis for the advantage of bradalumab among, the authors suggest genetic polymorphisms may play a role in difference in psoriasis manifestations and pathogenesis.
Study Finds Active Sunscreen Ingredients Exceed Plasma Concentration Thresholds
A pilot study
published in JAMA
demonstrated that active ingredients found in four on-the-market sunscreens exceeded FDA-established plasma-concentration threshold. The maximum avobenzone plasma concentrations were 1.8 ng/mL for cream, 4.3 ng/mL for lotion, 3.4 ng/mL for spray 2, and 4.0 ng/mL for spray 1. The study’s lead author, David Strauss, MD, PhD, of the FDA in Silver Spring, Maryland explained: “Systemic concentrations greater than 0.5 ng/mL were reached for all four products after four applications on day 1,” but made clear that “ "these results do not indicate that individuals should refrain from the use of sunscreen." The study protocol was approved by the FDA Research in Human Subjects Committee.